Johnson & Johnson stock: Company agrees to acquire Ollin for $2.2 billion
Published on 11/17/2026 at 13:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeal expands J&J eye-care pipeline
- Johnson & Johnson agreed to acquire clinical-stage biotech Ollin Biosciences and add the investigational antibody OLN324.
- OLN324 is in Phase 3 development for wet age-related macular degeneration and diabetic macular edema.
- Blackstone Life Sciences will fund the Phase 3 program under a separate agreement if the acquisition closes.
Johnson & Johnson said on Monday, November 16, that it had entered into a definitive agreement to acquire Ollin Biosciences for 2.2 billion US dollars upfront. The announcement, published in a Johnson & Johnson press release, said the transaction could bring additional regulatory and commercial milestone payments of up to approximately 1.125 billion US dollars.
Johnson & Johnson stock traded at 254.78 euros on Lang & Schwarz at 13:40 CET on Tuesday, November 17.
Ollin adds a late-stage eye program
The proposed acquisition would add Ollin's OLN324 to Johnson & Johnson's pipeline. The investigational bispecific antibody is designed to target vascular endothelial growth factor, or VEGF, and angiopoietin-2, known as Ang2. The company describes the therapy as a small-protein minibody intended to improve control of retinal fluid.
OLN324 is being developed for wet age-related macular degeneration and diabetic macular edema. Johnson & Johnson said the two conditions together affect more than 40 million people worldwide. The candidate remains investigational and is in Phase 3 development, leaving clinical and regulatory execution as key steps before any commercial opportunity can be assessed.
Funding structure limits near-term deal burden
Under a separate development funding agreement, Blackstone Life Sciences would pay Johnson & Johnson over multiple years to fully fund OLN324's Phase 3 development. In return, Blackstone would be eligible for selected regulatory and sales milestone payments as well as single-digit royalties. The funding arrangement is contingent on the acquisition closing.
Johnson & Johnson expects the acquisition to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions. The company said it will communicate the accounting treatment on or before closing. The proposed structure gives Johnson & Johnson access to a late-stage ophthalmology asset while shifting the cost of the pivotal development program to a separate funding partner, although future value still depends on clinical outcomes, approval and adoption.
What investors should watch next
The immediate milestones are completion of the acquisition, the related funding arrangement and progress in OLN324's Phase 3 program. For Johnson & Johnson, the transaction broadens its presence in retinal disease and adds another potential growth asset to its Innovative Medicine portfolio. The deal also carries the usual risks of a clinical-stage transaction, including development delays, regulatory setbacks, manufacturing challenges and commercial competition.
Johnson & Johnson stock facts
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Primary listing: New York Stock Exchange
- Lang & Schwarz quote: 254.78 euros at 13:40 CET on Tuesday, November 17, 2026
US healthcare shares trade against a broad market backdrop represented by the S&P 500.
